Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
about
Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomographyNeuraminidase-1: a novel therapeutic target in multistage tumorigenesisMechanisms of resistance to anti-EGFR therapy in colorectal cancerPotentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathwayContribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsAdvanced computational biology methods identify molecular switches for malignancy in an EGF mouse model of liver cancerActivation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesInsulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expressionMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapyA novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachEvaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.Targeting insulin-like growth factor axis in hepatocellular carcinoma.Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.An analysis of trends and growth factor receptor expression of GI carcinoid tumorsDiscovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.Proteomic analysis of Terminalia chebula extract-dependent changes in human lymphoblastic T cell protein expressionPET of EGFR expression with an 18F-labeled affibody molecule.Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityLIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis.Therapeutic destruction of insulin receptor substrates for cancer treatment.In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell CancerA phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancerInsulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.Research progress on criteria for discontinuation of EGFR inhibitor therapy.Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.
P2860
Q27304350-119F7245-97C1-425C-B894-45A71F5EF919Q28066130-56970A2C-B1FE-48EE-ABE7-E98BC3D74F23Q28074073-8571594D-87EA-46EA-A3D4-D6101F863EFEQ28534009-1A71CE06-4465-454E-AD89-C69D11173211Q28547357-D8A51A74-3CFF-4756-95CA-6EB5FD525322Q28741608-C6829F3B-A489-4592-8568-581F2020C969Q30424348-86BC88E0-EB4F-46A5-820F-F0691E3AD1CFQ30438487-349B156E-2351-4B7F-B43C-15FBD8F038D3Q33500359-E7658759-5AE8-4CEC-9C1B-8B2F25874306Q33684793-668257F8-BC09-457B-98C5-941F10B1C9A8Q33730375-E10C1D23-5888-4ED8-8AFB-2D5770B68D95Q33813730-B83F1DD3-4A0D-42D8-8601-5CEE43693769Q33828409-D84C72BF-F7C8-46C8-8E2D-ED7BF5F002F8Q33846405-A663ABCD-CBB4-4C53-9A10-B20534BADCCDQ33925323-216BD354-B6D3-4885-A85E-63CC77021A80Q33935045-4743476F-481D-4891-B462-A9AB63ECB01EQ33951057-0735499F-FC48-42FE-84D1-150E3EF6E48BQ33979359-1ED57266-2FFA-412E-80DA-A4C5C038144DQ33985773-4C0185BD-8F1A-44CD-A67B-25FF5541C339Q34172489-A6434235-3B0C-428E-AD42-F00B79F2970AQ34218840-D1B3BF6D-CDB1-4FC8-B49F-ECD7CB5E6F3DQ34429075-300F9D1C-EFD3-402D-89D2-77D199B36119Q34569071-D13888E6-C3A9-4EFF-ACA8-F963094F7225Q34612359-78374D28-5047-4449-AFE4-A495A8314C14Q35102025-5D828CE3-CA9F-48DA-82DC-9CBD519BB583Q35146077-8963E4B4-996A-4894-9C66-4D86AB94E95CQ35221829-F75A4DE0-F9C2-439A-A0C8-E334CA78351EQ35343877-0EB7DF54-F595-44BC-993F-C8BC7FAFDD3DQ35803276-E4BEC6CD-C90C-47C6-B259-4633471785B0Q35875753-2D0CB76C-C696-4FB3-A37B-A3E22C822E5DQ35982635-256D05C5-3350-4066-99C9-6DC3C56CEBA7Q35994860-9FE553DF-0A2C-47B8-96CB-BDA8283C2446Q36082594-332E39E5-1999-4CB8-9889-A441EB2C46B3Q36219713-9A4136EC-9939-4FDA-B191-3AFF62579F6FQ36272854-5A4F6399-D6E3-473D-A4DF-12AE75D39DB2Q36330264-1AA12343-21F9-4539-9121-F2B59969BCFFQ36357195-1B974470-FAF9-450F-87C1-68598D4F026AQ36393289-E682202B-4BF2-4376-8D1F-8FC04A0D6DE8Q36612550-72FA7632-E662-4BDC-8467-2DACD906215CQ36685345-F7430345-AE4B-40B6-81F1-4C9CF4E2E9AE
P2860
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Insulin-like growth factor-I r ...... east and prostate cancer cells
@ast
Insulin-like growth factor-I r ...... east and prostate cancer cells
@en
Insulin-like growth factor-I r ...... east and prostate cancer cells
@nl
type
label
Insulin-like growth factor-I r ...... east and prostate cancer cells
@ast
Insulin-like growth factor-I r ...... east and prostate cancer cells
@en
Insulin-like growth factor-I r ...... east and prostate cancer cells
@nl
prefLabel
Insulin-like growth factor-I r ...... east and prostate cancer cells
@ast
Insulin-like growth factor-I r ...... east and prostate cancer cells
@en
Insulin-like growth factor-I r ...... east and prostate cancer cells
@nl
P2093
P3181
P356
P1476
Insulin-like growth factor-I r ...... east and prostate cancer cells
@en
P2093
A E Wakeling
J M Knowlden
R I Nicholson
S Williams
P304
P3181
P356
10.1677/ERC.1.00799
P407
P50
P577
2004-12-01T00:00:00Z